Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas

Histopathology

Volumn 61, Issue 4, 2012, Pages 726-736

  Zhao, Li Li ^a   Xu, Kan Lun ^a   Wang, Shan Wei ^b   Hu, Bai Lai ^a   Chen, Li Rong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Fluorescence in situ hybridization; Glioma; Immunohistochemistry; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; BIOSYNTHESIS; BRAIN TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84871919141     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04354.x     Document Type: Article

References (58)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 2010; 60; 166-193.
2. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 1990; 28; 818-822.
3. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr. Neurosurg. 2005; 41; 292-299.
4. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int. J. Radiat. Oncol.Biol. Phys. 2005; 63; 704-710.
5. Brat DJ, Shehata BM, Castellano-Sanchez AA et al. Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol. 2007; 17; 276-281.
6. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366; 2-16.
7. Guillamo JS, de Bouard S, Valable S et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin. Cancer Res. 2009; 15; 3697-3704.
8. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71; 2454-2460.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003; 21; 3798-3807.
10. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res. 2000; 12; 107-112.
11. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997; 57; 4130-4140.
12. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J. Neuropathol. Exp. Neurol. 1992; 51; 84-90.
13. Nishikawa R, Ji XD, Harmon RC et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl Acad. Sci. USA 1994; 91; 7727-7731.
14. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int. J. Cancer 2004; 108; 643-653.
15. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. 2004; 72; 267-273.
16. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumorspecific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl Acad. Sci. USA 1998; 95; 5724-5729.
17. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. Targeted therapy: wave of the future. J. Clin. Oncol. 2005; 23; 1776-1781.
18. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002; 20; 1S-13S.
19. Ponz-Sarvise M, Rodriguez J, Viudez A et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J. Gastroenterol. 2007; 13; 5877-5887.
20. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-smallcell lung cancer. J. Natl Cancer Inst. 2005; 97; 643-655.
21. Mott RT, Turner KC, Bigner DD, McLendon RE. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. J. Neurosurg. 2008; 108; 330-335.
22. Varella-Garcia M, Diebold J, Eberhard DA et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 2009; 62; 970-977.
23. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin. Cancer Res. 2004; 10; 7820-7826.
24. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl. Immunohistochem. Mol. Morphol. 2006; 14; 91-96.
25. Lopez-Gines C, Gil-Benso R, Ferrer-Luna R et al. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod. Pathol. 2010; 23; 856-865.
26. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 2009; 16; 748-754.
27. Suri V, Das P, Pathak P et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-Oncol. 2009; 11; 274-280.
28. Nakamura M, Shimada K, Ishida E et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncol. 2007; 9; 113-123.
29. Bax DA, Gaspar N, Little SE et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 2009; 15; 5753-5761.
30. Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol. Pathol. 2000; 28; 164-170.
31. Ulutin C, Fayda M, Aksu G et al. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori 2006; 92; 407-411.
32. Larysz D, Kula D, Kowal M et al. Epidermal growth factor receptor gene expression in high grade gliomas? Folia Neuropathol. 2011; 49; 28-38.
33. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001; 61; 1122-1128.
34. Galanis E, Buckner J, Kimmel D et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol. 1998; 13; 717-724.
35. Newcomb EW, Cohen H, Lee SR et al. Survival of patients with glioblastomamultiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998; 8; 655-667.
36. Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J. Transl. Med. 2005; 3; 38.
37. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1996; 34; 809-915.
38. Etienne MC, Formento JL, Lebrun-Frenay C et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin. Cancer Res. 1998; 4; 2383-2390.
39. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003; 63; 6962-7690.
40. Pelloski CE, Ballman KV, Furth AF et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol. 2007; 25; 2288-2294.
41. Heimberger AB, Hlatky R, Suki D et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 2005; 11; 1462-1466.
42. Aldape KD, Ballman K, Furth A et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol. 2004; 63; 700-707.
43. Liu L, Backlund LM, Nilsson BR et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J. Mol. Med. (Berl.) 2005; 83; 917-926.
44. Torp SH, Helseth E, Dalen A, Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir. (Wien) 1992; 117; 182-186.
45. Ruano Y, Ribalta T, de Lope AR et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53alteration.Am. J.Clin.Pathol.2009;131;257-263.
46. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst. 2001; 93; 1246-1256.
47. Batchelor TT, Betensky RA, Esposito JM et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Cancer Res. 2004; 10; 228-233.
48. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years. Cancer 2005; 104; 825-832.
49. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52; 738-746.
50. Omuro AM. What is the relevance of determining EGFR-variant-III status in glioblastomas? Nat. Clin. Pract. Oncol. 2008; 5; 188-189.
51. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009; 27; 579-584.
52. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J. Neurooncol. 2005; 74; 77-86.
53. Broniscer A, Baker SJ, Stewart CF et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin. Cancer Res. 2009; 15; 701-707.
54. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005; 5; 341-354.
55. Bianco R, Troiani T, Tortora G, Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr. Relat. Cancer 2005; 12; 159-171.
56. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005; 353; 2012-2024.
57. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther. 2009; 9; 1087-1098.
58. Li G, Mitra S, Wong AJ. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurg. Clin. N. Am. 2010; 21; 87-93.